800 related articles for article (PubMed ID: 30862743)
1. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
[TBL] [Abstract][Full Text] [Related]
2. Highly Cross-Reactive and Protective Influenza A Virus H3N2 Hemagglutinin- and Neuraminidase-Specific Human Monoclonal Antibodies.
Piepenbrink M; Oladunni F; Nogales A; Khalil AM; Fitzgerald T; Basu M; Fucile C; Topham DJ; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
Microbiol Spectr; 2023 Aug; 11(4):e0472822. PubMed ID: 37318331
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.
Wohlbold TJ; Nachbagauer R; Xu H; Tan GS; Hirsh A; Brokstad KA; Cox RJ; Palese P; Krammer F
mBio; 2015 Mar; 6(2):e02556. PubMed ID: 25759506
[TBL] [Abstract][Full Text] [Related]
5. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
6. Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface.
Wolters RM; Ferguson JA; Nuñez IA; Chen EE; Sornberger T; Myers L; Oeverdieck S; Raghavan SSR; Kona C; Handal LS; Esilu TE; Davidson E; Doranz BJ; Engdahl TB; Kose N; Williamson LE; Creech CB; Gibson-Corley KN; Ward AB; Crowe JE
Immunity; 2024 Jun; 57(6):1413-1427.e9. PubMed ID: 38823390
[TBL] [Abstract][Full Text] [Related]
7. Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.
Gao J; Couzens L; Burke DF; Wan H; Wilson P; Memoli MJ; Xu X; Harvey R; Wrammert J; Ahmed R; Taubenberger JK; Smith DJ; Fouchier RAM; Eichelberger MC
mBio; 2019 Apr; 10(2):. PubMed ID: 30967460
[TBL] [Abstract][Full Text] [Related]
8. Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.
Madsen A; Dai YN; McMahon M; Schmitz AJ; Turner JS; Tan J; Lei T; Alsoussi WB; Strohmeier S; Amor M; Mohammed BM; Mudd PA; Simon V; Cox RJ; Fremont DH; Krammer F; Ellebedy AH
Immunity; 2020 Oct; 53(4):852-863.e7. PubMed ID: 32976769
[TBL] [Abstract][Full Text] [Related]
9. Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.
Job ER; Schotsaert M; Ibañez LI; Smet A; Ysenbaert T; Roose K; Dai M; de Haan CAM; Kleanthous H; Vogel TU; Saelens X
J Virol; 2018 Feb; 92(4):. PubMed ID: 29167342
[TBL] [Abstract][Full Text] [Related]
10. Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.
Fang F; Cai XQ; Chang HY; Wang HD; Yang ZD; Chen Z
Acta Virol; 2008; 52(2):107-12. PubMed ID: 18564897
[TBL] [Abstract][Full Text] [Related]
11. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
[TBL] [Abstract][Full Text] [Related]
12. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model.
Rosu ME; Kok A; Bestebroer TM; de Meulder D; Verveer EP; Pronk MR; Dekker LJM; Luider TM; Richard M; van den Brand JMA; Fouchier RAM; Herfst S
J Virol; 2022 Mar; 96(6):e0195921. PubMed ID: 35107371
[TBL] [Abstract][Full Text] [Related]
14. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
[TBL] [Abstract][Full Text] [Related]
15. Development of an Alternative Modified Live Influenza B Virus Vaccine.
Santos JJS; Finch C; Sutton T; Obadan A; Aguirre I; Wan Z; Lopez D; Geiger G; Gonzalez-Reiche AS; Ferreri L; Perez DR
J Virol; 2017 Jun; 91(12):. PubMed ID: 28381580
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the vaccine-induced influenza B virus hemagglutinin-specific antibody dependent cellular cytotoxicity response.
de Vries RD; Nieuwkoop NJ; Krammer F; Hu B; Rimmelzwaan GF
Virus Res; 2020 Feb; 277():197839. PubMed ID: 31837382
[TBL] [Abstract][Full Text] [Related]
17. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
18. The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017.
Catani JPP; Smet A; Ysenbaert T; Vuylsteke M; Bottu G; Mathys J; Botzki A; Cortes-Garcia G; Strugnell T; Gomila R; Hamberger J; Catalan J; Ustyugova IV; Farrell T; Stegalkina S; Ray S; LaRue L; Saelens X; Vogel TU
Elife; 2024 May; 12():. PubMed ID: 38805550
[TBL] [Abstract][Full Text] [Related]
19. Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice.
Gilchuk IM; Bangaru S; Gilchuk P; Irving RP; Kose N; Bombardi RG; Thornburg NJ; Creech CB; Edwards KM; Li S; Turner HL; Yu W; Zhu X; Wilson IA; Ward AB; Crowe JE
Cell Host Microbe; 2019 Dec; 26(6):715-728.e8. PubMed ID: 31757769
[TBL] [Abstract][Full Text] [Related]
20. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
